2. Signaling Pathways
  3. GPCR/G Protein
  4. Apelin Receptor (APJ)
  5. Apelin Receptor (APJ) Antagonist

Apelin Receptor (APJ) Antagonist

Apelin Receptor (APJ) Antagonists (4):

Cat. No. Product Name Effect Purity
  • HY-103254
    ML221
    		Antagonist 99.55%
    ML221 is a potent apelin (APJ) functional antagonist, inhibiting apelin-13-mediated activation of APJ, with IC50s of 0.70 μM in the cAMP assay, and 1.75 μM in the β-arrestin assay, and EC80 of 10 nM in both assays.
  • HY-122197
    ML339
    		Antagonist 99.88%
    ML339 is a selective CXCR6 antagonist with an IC50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC50 of 0.3 μM and 1.4 μM, respectively. ML339 has no inhibitory effect on CXCR5，CXCR4，CXCR6 and apelin receptor (APJ), with IC50 >79 μM. ML339 has the potential to promote the development of prostate cancer research.
  • HY-P3162A
    (Ala13)-Apelin-13 TFA
    		Antagonist 99.25%
    (Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway.
  • HY-P3162
    (Ala13)-Apelin-13
    		Antagonist
    (Ala13)-Apelin-13 is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 inhibits gastric motility through vagal cholinergic pathway.